In our study we aimed to evaluate the prognostic and therapeutic significance of proangiogenic ligands and receptors (c-Met, HGF, VEGFR2) and MVD, specifically in a clinical population of bevacizumab-treated recurrent GBM patients. Here, MET is linked to glioblastoma.